• Mashup Score: 2
    EA4151 Home Page - ECOG-ACRIN Cancer Research Group - 1 year(s) ago

    United StatesAKAnchorageAlaska Breast Care and Surgery LLCContact: Site Public ContactEmail: AKPAMC.OncologyResearchSupport@providence.orgAlaska Oncology and Hematology LLCContact: Site Public ContactEmail: AKPAMC.OncologyResearchSupport@providence.orgAlaska Women’s Cancer CareContact: Site Public ContactEmail: AKPAMC.OncologyResearchSupport@providence.orgAnchorage Associates in Radiation…

    Source: ECOG-ACRIN Cancer Research Group
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of timfenske
      timfenske

      @rosslevinemd @DrChrisHourigan We are hoping ECOG4151 will change this in mantle cell lymphoma. Close to accrual and will be nearly 700 pts, randomized transplant vs no transplant in the MRD neg pts https://t.co/lZh1W1Wdva

  • Mashup Score: 0
    Program Guide – ASCO Meeting Program Guide - 2 year(s) ago

    AuthorsClémentine SarkozyInstitut Curie, Saint Cloud, Paris, FranceClémentine Sarkozy, Catherine Thieblemont, Lucie Oberic, Anne Moreau, Krimo Bouabdallah, Gandhi Laurent Damaj, Thomas Gastinne, Olivier Casasnovas, Corinne Haioun, Roch Houot, Eric Van Den Neste, Morgane Cheminant, Herve Ghesquieres, Vincent Ribrag, Franck Morschhauser, Mary Callanan, Remi Gressin, Olivier Hermine, Steven Le…

    Source: meetings.asco.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of timfenske
      timfenske

      For those attending ASCO, any theories as to why the OS benefit initially seen in the LYSA LyMa MCL trial, is no longer significant (p=0.09) with longer f/u? Abstract says no increase in infectious deaths or relapses after R maint ended https://t.co/BcNRZnPu5X

  • Mashup Score: 5
    Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial - PubMed - 2 year(s) ago

    Chimeric antigen receptor (CAR) T cells targeting CD19 are a breakthrough treatment for relapsed, refractory B cell malignancies1-5. Despite impressive outcomes, relapse with CD19– disease remains a challenge. We address this limitation through a first-in-human trial of bispeci …

    Source: PubMed
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of timfenske
      timfenske

      @dgermain21 @DrPaulyDeSantis @Dr_Daniel_Molin @Eddie_Cliff @DrLaCasce @DanaFarber @DrAEvens @SoniSmithMD @BioAscend You don’t even need a full GMP facility. We do our point of care CART using the Miltenyi prodigy system. Fits on a table top and internally meets GMP criteria. https://t.co/I8N0ffN1Fp https://t.co/AgO5eQ3v6A

  • Mashup Score: 1
    Chicago Lymphoma Symposium 2023 Home | Bio Ascend - 2 year(s) ago

    Chicago Lymphoma Symposium 2023 Home | Bio Ascend is an independent medical education company committed to supporting oncology and hematology healthcare

    Source: Bio Ascend
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of timfenske
      timfenske

      Key dates for #IUCLS2023. Don’t miss the opportunity to join us live in Chicago on 4/21 & 4/22 for the 20-year anniversary of this historic symposium. Register today to secure your seat: https://t.co/majwyYWhSo https://t.co/Pv3FOZgcbj

  • Mashup Score: 3
    Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era? - PubMed - 2 year(s) ago

    For relapsed chemosensitive diffuse large B-cell lymphoma (DLBCL), consolidation with autologous hematopoietic cell transplantation (auto-HCT) is a standard option. With the approval of anti-CD19 chimeric antigen receptor T cells in 2017, the Center for International Blood and Marrow Transplant Rese …

    Source: PubMed
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of timfenske
      timfenske

      @smbenlazar Just because relapse is within 1 year, do not rule out auto-HCT. As long as at least a good PR by PET with 2nd line (salvage), 41% appear curesdz. Even better if CR after salvage. And you still have CAR for 3rd line if needed https://t.co/yTpICG4nHf

Load More